Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.

@article{SenekowitschSchmidtke2001HighlyST,
  title={Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.},
  author={Reingard Senekowitsch-Schmidtke and Christoph P Schuhmacher and K F Becker and Tuomo K. Nikula and Christof Seidl and Ingrid Becker and Matthias Miederer and Christos Apostolidis and Christian Adam and Reid M Huber and Elisabeth Kremmer and Karin Fischer and Markus Schwaiger},
  journal={Cancer research},
  year={2001},
  volume={61 7},
  pages={2804-8}
}
A monoclonal antibody (E-cadherin delta 9-1) directed against a characteristic E-cadherin mutation (in-frame deletion of exon 9), found in diffuse-type gastric cancer but not in any normal tissue, was conjugated with the high linear energy transfer alpha-emitter 213Bi and tested for its binding specificity in s.c. and i.p. nude mice tumor models. After intratumoral application in s.c. tumors expressing mutant E-cadherin, the 213Bi-labeled antibody was specifically retained at the injection site… CONTINUE READING